KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 98 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $41,000 | +2.5% | 4,226 | -5.9% | 0.00% | – |
| Q2 2023 | $40,000 | +263.6% | 4,492 | +225.7% | 0.00% | – |
| Q1 2023 | $11,000 | -62.1% | 1,379 | -68.2% | 0.00% | – |
| Q4 2022 | $29,000 | -79.7% | 4,332 | -56.0% | 0.00% | – |
| Q3 2022 | $143,000 | +14200.0% | 9,847 | +7035.5% | 0.00% | – |
| Q2 2022 | $1,000 | -95.0% | 138 | -90.0% | 0.00% | – |
| Q1 2022 | $20,000 | -69.7% | 1,376 | -72.3% | 0.00% | – |
| Q4 2021 | $66,000 | +61.0% | 4,971 | +113.8% | 0.00% | – |
| Q3 2021 | $41,000 | -41.4% | 2,325 | -19.8% | 0.00% | – |
| Q2 2021 | $70,000 | +52.2% | 2,900 | +62.2% | 0.00% | – |
| Q1 2021 | $46,000 | +253.8% | 1,788 | +166.9% | 0.00% | – |
| Q4 2020 | $13,000 | – | 670 | +3090.5% | 0.00% | – |
| Q3 2020 | $0 | – | 21 | -34.4% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 32 | -97.5% | 0.00% | – |
| Q4 2019 | $22,000 | – | 1,263 | +12530.0% | 0.00% | – |
| Q3 2018 | $0 | – | 10 | +900.0% | 0.00% | – |
| Q1 2017 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |